Addyi at Relive Nations
Addyi (flibanserin) is the first and only FDA-approved medication specifically designed to treat acquired, generalized HSDD in premenopausal women. Addyi works by rebalancing neurotransmitters in the brain that are linked to sexual desire and mood regulation. By restoring this balance, Addyi helps rekindle sexual interest and reduces the distress associated with HSDD.
Benefit |
Description |
|---|---|
| Improves Sexual Desire | Addyi helps increase sexual desire in premenopausal women with HSDD, addressing the root cause of the disorder. |
| Enhances Emotional Well-being | By alleviating the distress associated with low sexual desire, Addyi can improve overall emotional and psychological well-being. |
| Non-Hormonal Treatment | Unlike some other treatments, Addyi is a non-hormonal option, making it suitable for women who cannot or prefer not to use hormonal therapies. |
| Convenient Once-Daily Dosage | Addyi is taken once daily at bedtime, making it easy to incorporate into a daily routine and ensuring consistent treatment. |
Understanding Hypoactive Sexual Desire Disorder (HSDD)
Hypoactive Sexual Desire Disorder (HSDD) is a medical condition affecting many premenopausal women, characterized by a persistent lack of sexual desire that causes significant distress or interpersonal difficulties.
Unlike other causes of low sexual desire, HSDD is not due to underlying medical or psychological issues, making accurate diagnosis essential for effective treatment. Addressing HSDD can greatly improve the quality of life and emotional well-being of those affected.
FAQs About Addyi for HSDD
